Deal Watch, Am­gen: ‘We’ve got a num­ber of pret­ty in­ter­est­ing prospects’

Last fall, the Fi­nan­cial Times man­aged to get heads to turn when it quot­ed sources say­ing that Am­gen was look­ing for an ac­qui­si­tion worth up to $10 bil­lion. It would be a buy­out that was di­rect­ly prod­uct/sales re­lat­ed. And it was no co­in­ci­dence that the tempt­ing key fig­ure was al­most ex­act­ly what it paid to get Onyx in 2013.

We’re still wait­ing for that big ac­qui­si­tion.

The Big Biotech’s last M&A deal hit last fall, when it picked up Dez­i­ma, a CETP ac­qui­si­tion with a $300 mil­lion up­front that land­ed just ahead of an­oth­er late-stage CETP fi­as­co at Eli Lil­ly. That pret­ty much fit the bill for all of Am­gen’s M&A work since Onyx land­ed.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER